Can an IDO1 inhibitor boost immunotherapy against liver cancer?
Disease control
Terminated
This trial is testing whether combining an experimental IDO1 inhibitor (BMS-986205) with the immunotherapy drug nivolumab can shrink tumors or slow disease progression in people with advanced liver cancer that cannot be surgically removed. The study enrolls adults whose cancer ha…
Phase: PHASE1, PHASE2 • Sponsor: Edward Kim • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC